<DOC>
	<DOCNO>NCT00003299</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether cisplatin , etoposide , paclitaxel effective cisplatin etoposide alone treat patient extensive-stage small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness cisplatin plus etoposide without paclitaxel treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Plus Etoposide With Without Paclitaxel Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether addition paclitaxel standard chemotherapy treatment comprise etoposide cisplatin improve survival patient extensive stage small cell lung cancer . II . Compare tumor response rate failure-free survival patient treat regimen . III . Describe compare toxic effect associate regimens patient . OUTLINE : This randomize study . Patients stratify accord performance status gender . Patients randomize one two treatment arm . Arm I : Patients receive cisplatin IV day 1 etoposide IV 1 hour day 1-3 . Arm II : Patients receive paclitaxel IV 3 hour day 1 cisplatin etoposide arm I . Patients receive filgrastim ( G-CSF ) subcutaneously day 4-18 . Treatment repeat arm every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow least every 2 month 2 year , every 4 month 1 year , least every 6 month 2 year . PROJECTED ACCRUAL : Approximately 670 patient ( 335 per arm ) accrue study within 16 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically document extensive stage small cell carcinoma bronchus Measurable evaluable disease No pleural effusion , bone scan abnormality , bone marrow biopsy evidence disease PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 01 Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2 time normal Renal : Serum creatinine great 1.5 mg/dL Cardiovascular : No cardiac disease Pulmonary : No interstitial pneumonia No fibroid lung Other : Not pregnant nursing Fertile patient must use effective contraception No psychiatric illness No malabsorption disorder No uncontrolled infection No uncontrolled diabetes mellitus No prior concurrent malignancy within past 5 year except carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy small cell lung cancer No concurrent chemotherapy Endocrine therapy : No chronic steroid therapy ( except steroid adrenal failure hormone nondisease related condition ) Radiotherapy : No prior pelvic mediastinal radiotherapy Surgery : Not specify Other : No concurrent anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>